Ranibizumab 0.5 mg
CRFB002E2302
Phase 3 small_molecule completed
Quick answer
Ranibizumab 0.5 mg for Central Retinal Vein Occlusion is a Phase 3 program (small_molecule) at Novartis Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Pharmaceuticals
- Indication
- Central Retinal Vein Occlusion
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed